Before considering treatment with STELARA, it is important to understand that eligibility is determined not only by the specific medical condition but also by the patient's age. The U.S. Food and Drug Administration (FDA) has approved STELARA for various conditions, each with its own age requirements. Patients and caregivers should always consult with a healthcare provider to determine if STELARA is appropriate based on the patient's age and diagnosis. This section details the age limits for STELARA for its approved indications.
STELARA for Plaque Psoriasis
STELARA is approved by the FDA for the treatment of moderate to severe plaque psoriasis in adults and in pediatric patients aged 6 years and older who are candidates for systemic therapy or phototherapy. Clinical studies, such as CADMUS and CADMUS Junior, have supported the use of STELARA in adolescents (ages 12–17) and younger children (ages 6–11). For adult patients with plaque psoriasis, there is no specific upper age limit for receiving STELARA, provided a healthcare provider assesses its safety and suitability.
STELARA for Psoriatic Arthritis
STELARA is also approved for the treatment of active psoriatic arthritis. This indication includes both adult patients aged 18 and older, as well as pediatric patients aged 6 years and older. STELARA can be used alone or in combination with methotrexate.
STELARA for Crohn's Disease and Ulcerative Colitis
For moderately to severely active Crohn's disease and ulcerative colitis, STELARA is currently indicated only for adult patients aged 18 years and older. While an application for pediatric use in Crohn's disease was pending with the FDA as of September 2025, there are no FDA-approved indications for the use of STELARA in pediatric patients with ulcerative colitis at this time.
Dosage Considerations for Pediatric Patients
When STELARA is used in pediatric patients aged 6 years and older, dosage is determined based on the child's body weight. This approach helps ensure that the appropriate amount of medication is administered for safety and effectiveness.
Here is a comparison of age eligibility and dosing considerations for different conditions:
| Condition | Minimum Age | Pediatric Dosing Considerations | Adult Dosing Considerations |
|---|---|---|---|
| Plaque Psoriasis | 6 years old | Dosage is weight-based. The medication is typically administered at specific intervals. | Dosage may be weight-based. Administration follows a specific schedule. |
| Psoriatic Arthritis | 6 years old | Dosage is weight-based. Administration follows a specific schedule. | Dosage may vary. Administration follows a specific schedule, potentially adjusted for certain factors. |
| Crohn's Disease | 18 years old | Not currently approved. | Treatment involves an initial intravenous infusion, followed by subcutaneous injections at regular intervals. |
| Ulcerative Colitis | 18 years old | Not currently approved. | Treatment involves an initial intravenous infusion, followed by subcutaneous injections at regular intervals. |
Conclusion
The age limits for STELARA are condition-specific and must be evaluated by a medical professional. While children as young as six may be eligible for treatment for certain skin and joint conditions, the medication's use for inflammatory bowel diseases is currently limited to adults aged 18 and over. It is essential for prospective patients and their caregivers to have a detailed discussion with their doctor to review the safety and suitability of STELARA for their individual circumstances. Staying informed about the FDA-approved indications is crucial for making informed treatment decisions. For further information, including complete prescribing information and safety guidelines, the manufacturer's official website can serve as an authoritative resource.
Disclaimer:
This article provides general information and is not a substitute for medical advice. Always consult with a qualified healthcare professional before making any decisions about your treatment plan. The information on age limits and indications is based on FDA approvals and is subject to change.
Note: A healthcare provider must determine if STELARA is the right course of treatment for a patient and provide guidance on its administration.
